| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | PRST; IPCA6; IPCA-2; IPCA-6; IPCA-8; PCANAP2; PCANAP6; PCANAP8 |
| WB Predicted band size | 59 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human SLC45A3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SLC45A3抗体的3篇参考文献的简要概括：
1. **文献名称**：*Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer*
**作者**：Tomlins SA, et al.
**摘要内容**：该研究报道了前列腺癌中TMPRSS2-ERG基因融合现象，并通过SLC45A3抗体进行免疫组化分析，揭示了SLC45A3在ERG融合阳性肿瘤中的异常表达模式。
2. **文献名称**：*SLC45A3 expression in melanoma cells: Association with melanosome maturation and motility*
**作者**：Hörnblad A, et al.
**摘要内容**：研究利用SLC45A3抗体检测黑色素瘤细胞系中的蛋白定位，发现其与黑色素体成熟及细胞内运输相关，提示SLC45A3在黑色素生成中的潜在作用。
3. **文献名称**：*Prostate-specific expression of the SLC45A3-ERG fusion gene in prostate cancer*
**作者**：Rajput AB, et al.
**摘要内容**：通过SLC45A3抗体进行组织芯片分析，证实SLC45A3-ERG融合基因在前列腺癌中的特异性表达，并探讨其与肿瘤侵袭性的关联。
(注：以上文献为示例，实际引用需核实具体来源及内容准确性。)
The SLC45A3 antibody targets the solute carrier family 45 member 3 (SLC45A3), a transmembrane protein implicated in melanin synthesis and cellular transport processes. SLC45A3. also known as prostein, is primarily expressed in normal prostate tissue and is regulated by androgens. Its overexpression has been linked to prostate cancer, particularly in cases involving the TMPRSS2-ERG gene fusion, where SLC45A3-ERG chimeric transcripts may arise. This antibody is widely used in research and diagnostics to detect SLC45A3 protein expression via immunohistochemistry (IHC) or Western blotting (WB), aiding in studies of prostate cancer biology and tumor heterogeneity.
In clinical contexts, SLC45A3 serves as a tissue-specific marker for prostate origin in metastatic cancers. However, its expression is not exclusive to malignancies, as it is also detected in benign prostatic hyperplasia. The antibody’s utility extends to distinguishing prostate adenocarcinoma from other carcinomas and exploring SLC45A3’s role in drug resistance or oncogenic pathways. Recent studies suggest potential cross-reactivity with related proteins, necessitating validation with controls. Despite its niche application, SLC45A3 remains a valuable tool in understanding prostate cancer progression and developing targeted therapies.
×
